首页 | 本学科首页   官方微博 | 高级检索  
检索        


The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design
Institution:1. Pediatric Clinical Research Office, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands;2. Duchenne Parent Project, Veenendaal, the Netherlands;3. Alstrom Syndrome UK, Torquay, Devon, UK;4. PSC Patients Europe;5. Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland;6. Polish Hemophilia Society, Warsaw, Poland;7. Child Development and Exercise Center, Wilhelmina Children’s Hospital, University Medical Center Utrecht, the Netherlands;8. Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, the Netherlands;9. Julius Center, University Medical Center Utrecht, Utrecht, the Netherlands
Abstract:In clinical trials, it is relevant to ask patients and/or their caregivers which aspects concerning their disease they consider important to measure when a new intervention is being investigated. Those aspects, useful as outcome measures in a trial, are of pivotal importance for the result of the trial and the subsequent decision-making. In rare diseases the choice of outcome measures may be even more important, due to the small numbers and heterogeneity of the patients that are included.We have developed a tool to involve patients in the determination of outcome measures and the choice of measurement instruments. This tool was developed together with a patient think tank, consisting of a group of rare disease patient representatives, and by interviewing end users. We have road-tested our tool in an ongoing trial, and evaluated it during a focus group meeting.The tool consists of three steps: 1) Preparation, 2) Consultation of patients, 3) Follow-up during which the consultation results are implemented in the trial design.The tool provides guidelines for researchers to include the patient’s opinion in the choice of outcome measures in the trial design stage. We describe the development of the POWER-tool (Patient participation in Outcome measure WEighing for Rare diseases), and first experiences of the tool in an ongoing trial.
Keywords:Patient involvement  Outcomes  Trial design  Rare diseases
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号